In the midst of a comprehensive cost cutting program rumored to include thousands of job losses, Teva Pharmaceutical Industries' (NYSE: TEVA) chief financial officer Eyal Desheh is about to quit, Israeli press reports.
Mr Desheh would be the latest in a spate of executive departures at the embattled drugmaker, after generics chief executive Siggi Olafsson abruptly downed tools in December, and CEO Erez Vigodman elected not to continue in post earlier this year.
Managerial turbulence at Teva is not confined to the recent past. At times, the company’s boardroom has appeared to host more drama than an episode of The Apprentice.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze